Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
News|Videos|September 10, 2024
Editorial Advisory Board Spotlight: Susan J. Schniepp
Author(s)Susan Haigney
Susan J. Schniepp, member of the editorial advisory boards for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International, provides an update on her experience working in the pharmaceutical industry and what she sees for the industry’s future.
Advertisement
The PharmTech Group’s Editorial Advisory Boards (EABs) provide our editors with expert insights into the development, manufacturing, and quality issues impacting the bio/pharmaceutical industry. EAB members offer valuable input to our editors by reviewing editorial submissions and advising on relevant topics for the magazines and our websites.
This Editorial Advisory Board Spotlight features Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs company. Susan has been a member of the EAB for several years and a regular contributor to our Ask the Expert print and video series. Susan has offered thought leadership and expert insight into quality and regulatory concerns for our publications. She has also served as the past-chair of the Parenteral Drug Association and was previously a chair with the US Pharmacopeia.
Click the video above to learn more about Susan and her views on the industry.
Advertisement
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement